Legal & General Group
TLIS

Legal & General Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Legal & General Group’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-72
Closed -$2K – 3696
2022
Q1 		$2K Hold
72
– – ﹤0.01% 3555
2021
Q4 		$4K Hold
72
– – ﹤0.01% 3556
2021
Q3 		$7K Hold
72
– – ﹤0.01% 3470
2021
Q2 		$12K Sell
72
-17
-19% -$2.89K ﹤0.01% 3406
2021
Q1 		$17K Buy
+89
New +$22.2K ﹤0.01% 3193

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legal & General Group's TLIS Position: Q2 2022 in Review

Legal & General Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 72 shares — an estimated $2K sold.

Legal & General Group first reported a position in TLIS in Q1 2021 and held it in 5 quarters. The position peaked at $17K in Q1 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Legal & General Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 72 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $2K.
  • Legal & General Group first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 5 quarters.
  • Legal & General Group's Talis Biomedical Corporation Common Stock position peaked at $17K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.